A natural small molecule‐mediated inhibition of alpha‐synuclein aggregation leads to neuroprotection in Caenorhabditis elegans
Authors:
- Tulika SrivastavaTSTulika Srivastava
- Divya TyagiDTDivya Tyagi
- Siraj FatimaSFSiraj Fatima
- Malur Thirumalesh Vishnu SathyanMSMalur Thirumalesh Vishnu Sathyan
- Ritu RajRRRitu Raj
- Aniket SharmaASAniket Sharma
- Minal ChaturvediMCMinal Chaturvedi
- Meetali SinhaMSMeetali Sinha
- Sonia Kumari ShishodiaSSSonia Kumari Shishodia
- Dinesh KumarDKDinesh Kumar
- Sandeep K. SharmaSSSandeep K. Sharma
- Jata ShankarJSJata Shankar
- 10 July 2023
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1640-1654
Abstract
Small molecules are being explored intensively for their applications as therapeutic molecules in the management of metabolic and neurological disorders. The natural small molecules can inhibit protein aggregation and underlying cellular pathogenesis of neurodegenerative diseases involving multi‐factorial mechanisms of action. Certain natural small molecular inhibitors of pathogenic protein aggregation are highly efficient and have shown promising therapeutic potential. In the present study, Shikonin (SHK), a natural plant‐based naphthoquinone has been investigated for its aggregation inhibition activity against α‐synuclein (α‐syn) and the neuroprotective potential in Caenorhabditis elegans (C. elegans). SHK significantly inhibited aggregation of α‐syn at sub‐stochiometric concentrations, delayed the linear lag phase and growth kinetics of seeded and unseeded α‐syn aggregation. The binding of SHK to the C‐terminus of α‐syn maintained α‐helical and disordered secondary structures with reduced beta‐sheet content and complexity of aggregates. Further, in C. elegans transgenic PD models, SHK significantly reduced α‐syn aggregation, improved locomotor activity and prevented dopaminergic (DA) neuronal degeneration, indicating the neuroprotective role of SHK. The present study highlights the potential of natural small molecules in the prevention of protein aggregation that may further be explored for their therapeutic efficacy in the management of protein aggregation and neurodegenerative diseases. imageKeywords
Funding Information
- Council of Scientific and Industrial Research, India
- Council of Scientific and Industrial Research, India
This publication has 68 references indexed in Scilit:
- -Synuclein in Parkinson's DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicityProceedings of the National Academy of Sciences, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Robust single-particle tracking in live-cell time-lapse sequencesNature Methods, 2008
- Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-SynucleinJournal of Biological Chemistry, 2008
- EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomersNature Structural & Molecular Biology, 2008
- C. elegans Model Identifies Genetic Modifiers of α-Synuclein Inclusion Formation During AgingPLOS Genetics, 2008
- Relationships between the Sequence of α-Synuclein and its Membrane Affinity, Fibrillization Propensity, and Yeast ToxicityJournal of Molecular Biology, 2007
- Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates FibrilsChemistry & Biology, 2004
- The Protein Data BankNucleic Acids Research, 2000